Business Context and Reporting Period
Company: Actinium Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 16, 2020
Event: Amendment to Certificate of Incorporation.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a corporate governance report regarding capital structure.
Material Changes
- Authorized Share Increase: The Company increased its authorized common stock from 600,000,000 shares to 1,000,000,000 shares.
- Regulatory Filing: The Certificate of Amendment was filed with the Secretary of State of Delaware on June 16, 2020.
- Approval History: The amendment was previously approved by the Board of Directors on October 18, 2019, and by stockholders at the Annual Meeting on December 18, 2019.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports the execution of a previously approved corporate action.
Investor Verification Checklist
- Verify the effective date of the share increase with the Delaware Secretary of State.
- Review the definitive proxy statement filed on November 25, 2019, for details on the rationale for the increase.
- Confirm the current number of issued and outstanding shares to assess potential dilution impact.